What is the recommended weight‑based dosing of low‑molecular‑weight heparin (e.g., enoxaparin) for deep vein thrombosis prophylaxis, including adjustments for obesity, renal impairment, thrombocytopenia, and appropriate duration of therapy?

Weight-Based LMWH Dosing for DVT Prophylaxis

Standard Prophylactic Dosing

For most hospitalized patients, administer enoxaparin 40 mg subcutaneously once daily for the duration of hospitalization or until fully ambulatory. 1

• Continue prophylaxis for at least 7–10 days in surgical patients 1
• Extend prophylaxis up to 4 weeks (28–35 days) after major cancer surgery in high-risk patients with limited mobility, obesity (BMI >30 kg/m²), prior VTE history, or prolonged operative time 1

---

Obesity Adjustments

Class I–II Obesity (BMI 30–39.9 kg/m²)

Increase from standard 40 mg once daily to either 40 mg subcutaneously every 12 hours OR weight-based dosing at 0.5 mg/kg every 12 hours, because standard fixed dosing produces inadequate anti-Xa levels in this population. 2

• Fixed 40 mg once daily is consistently inadequate due to strong negative correlation between body weight and anti-Xa levels 3, 2
• Target prophylactic anti-Xa levels of 0.2–0.5 IU/mL measured 4–6 hours after dosing 1, 2

Class III Obesity (BMI ≥40 kg/m² or weight >120 kg)

Use 40 mg subcutaneously every 12 hours as the preferred regimen, or alternatively 0.5 mg/kg every 12 hours. 1, 2

• Weight-based prophylaxis at 0.5 mg/kg every 12 hours reliably achieves target anti-Xa levels (0.2–0.5 IU/mL) in morbidly obese patients 4
• Mandatory anti-Xa monitoring is required for all patients with BMI ≥40 kg/m² receiving any enoxaparin regimen 2
• A prospective study in morbidly obese medical patients (average weight 135.6 kg, BMI 48.1 kg/m²) using 0.5 mg/kg once daily achieved average peak anti-Xa of 0.25 IU/mL without bleeding events 4

---

Renal Impairment Adjustments

Severe Renal Impairment (CrCl <30 mL/min)

Reduce prophylactic dose to 30 mg subcutaneously once daily, because enoxaparin clearance falls by 44% and bleeding risk increases 2.25-fold without adjustment. 5, 1

• Enoxaparin clearance shows strong linear correlation with creatinine clearance (R=0.85, P<0.001) 3, 5
• Anti-Xa clearance is reduced by 39% in severe renal impairment, with drug exposure increasing 35% after repeated dosing 5
• Monitor anti-Xa levels in all patients with CrCl <30 mL/min receiving prolonged therapy, targeting 0.5–1.5 IU/mL measured 4–6 hours after dosing (after 3–4 consecutive doses) 5, 1
• Consider switching to unfractionated heparin (5,000 units subcutaneously every 8–12 hours) as the preferred alternative, because UFH does not require renal dose adjustment 3, 5

Moderate Renal Impairment (CrCl 30–60 mL/min)

Consider reducing dose by 25% to 30 mg once daily, although this is not universally mandated. 5, 1

• Enoxaparin clearance is reduced by 31% in moderate renal impairment 5, 1
• Close clinical monitoring is advised despite absence of mandatory dose reduction 5

Combined Obesity and Renal Impairment

When obesity coexists with severe renal impairment (CrCl <30 mL/min), strongly prefer unfractionated heparin over enoxaparin due to risk of bioaccumulation. 2

---

Therapeutic Dosing for Established VTE

Standard Therapeutic Regimen

For treatment of confirmed DVT or PE, use enoxaparin 1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily. 1

• Continue for minimum 5–10 days, overlapping with warfarin until INR ≥2.0 for two consecutive days 1
• Target therapeutic anti-Xa levels: 0.6–1.0 IU/mL for twice-daily dosing (measured 4 hours post-dose) 3, 1
• Target therapeutic anti-Xa levels: 1.0–1.5 IU/mL for once-daily dosing 1

Obesity Adjustments for Therapeutic Dosing

For patients with BMI ≥40 kg/m² or weight >100 kg requiring therapeutic anticoagulation, reduce to 0.8 mg/kg every 12 hours instead of standard 1 mg/kg dosing. 2, 6

• Standard 1 mg/kg dosing produces supratherapeutic levels in the majority of severely obese patients 2
• A systematic review found that 0.75–0.85 mg/kg dosing achieved therapeutic anti-Xa levels in 66% of obese patients, compared to only 42% with ≥0.95 mg/kg dosing 6
• Mandatory anti-Xa monitoring is required for all patients with BMI ≥40 kg/m² receiving therapeutic doses 2
• Most bleeding events (85.2%) occurred with doses ≥0.95 mg/kg in obese patients 6

Renal Impairment Adjustments for Therapeutic Dosing

For severe renal impairment (CrCl <30 mL/min), reduce therapeutic dose to 1 mg/kg subcutaneously once every 24 hours (instead of every 12 hours). 5, 1

• Without dose adjustment, therapeutic enoxaparin increases major bleeding nearly 4-fold (8.3% vs 2.4%; OR 3.88) 5
• Empirical dose reduction eliminates this excess bleeding risk (0.9% vs 1.9%; OR 0.58) 5

---

Special Populations

Cancer-Associated VTE

Continue enoxaparin for minimum 6 months and indefinitely while cancer remains active or under treatment. 1

• After the first month, consider dose reduction to 75–80% of initial dose (e.g., from 1 mg/kg to 0.75–0.8 mg/kg every 12 hours) 1
• LMWH monotherapy is strongly favored over oral anticoagulants for entire treatment duration in active cancer 1

Pregnancy with Class III Obesity

Use intermediate prophylactic dosing of 40 mg every 12 hours OR 0.5 mg/kg every 12 hours. 1

• Monitor anti-Xa levels in pregnant patients receiving therapeutic-intensity enoxaparin 1

Elderly Patients (≥75 years)

For prophylaxis, use standard 40 mg once daily without age-based dose reduction. 1

• For therapeutic dosing in elderly patients with STEMI receiving fibrinolysis, omit the initial IV bolus and use reduced dose of 0.75 mg/kg every 12 hours (maximum 75 mg per dose) 1

Low Body Weight (<50 kg)

Reduce prophylactic dose to 30 mg once daily in patients weighing <50 kg. 1

• Consider anti-Xa monitoring in underweight patients, especially when combined with renal impairment 1

---

Timing with Neuraxial Anesthesia

Prophylactic enoxaparin (40 mg daily) may be started ≥4 hours after catheter removal but no earlier than 12 hours after the neuraxial block. 1

• Intermediate or therapeutic doses (40 mg every 12 hours) may be started ≥4 hours after catheter removal but no earlier than 24 hours after the block 1

---

Monitoring Recommendations

Anti-Xa Monitoring Indications

Monitor anti-Xa levels in the following populations: 3, 1, 2

• All patients with CrCl <30 mL/min receiving prolonged therapy
• All patients with BMI ≥40 kg/m² receiving any enoxaparin regimen
• Pregnant patients receiving therapeutic doses
• Patients with extreme body weight (<50 kg)

Monitoring Technique

• Draw anti-Xa levels 4–6 hours after dosing, after 3–4 consecutive doses have been administered 5, 1
• Prophylactic target range: 0.2–0.5 IU/mL 1, 2
• Therapeutic target range (twice daily): 0.6–1.0 IU/mL 3, 1
• Therapeutic target range (once daily): 1.0–1.5 IU/mL 1

Platelet Monitoring

Monitor platelet counts every 2–3 days from day 4 through day 14 to screen for heparin-induced thrombocytopenia. 1

• Enoxaparin carries substantially lower HIT risk than unfractionated heparin (≈1% vs up to 5%) 1

---

Critical Pitfalls to Avoid

• Never use standard 40 mg once daily prophylaxis in Class III obesity (BMI ≥40 kg/m²) – this consistently produces inadequate anticoagulation 2
• Never use standard 1 mg/kg twice daily therapeutic dosing in BMI >40 kg/m² without anti-Xa monitoring – this produces supratherapeutic levels and excess bleeding 2, 6
• Never fail to adjust dose for severe renal impairment (CrCl <30 mL/min) – this is the most frequent error, leading to drug accumulation and 2.25-fold increased bleeding risk 5, 1
• Never switch between enoxaparin and unfractionated heparin during the same hospitalization – this increases bleeding risk 5
• Never administer enoxaparin within 10–12 hours before neuraxial procedures – this risks spinal hematoma 1

---

Duration of Therapy

Provoked DVT/PE

Treat for exactly 3 months if DVT occurred due to major reversible risk factor (surgery, trauma). 1

Unprovoked DVT/PE

Treat for minimum 3–6 months initially, then continue indefinitely. 1

Cancer-Associated VTE

Treat for minimum 6 months and indefinitely while cancer remains active or under treatment. 1